Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDI-2517 SAD and MAD Study in Healthy Participants
NCT07220889Phase 1Completed
- Sponsor
- MDI Therapeutics
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MDI-2517 (5 arms), sponsored by MDI Therapeutics. Primary endpoint: Safety and Tolerability. Started Nov 2025; status: completed.
02
Drugs
MDI-2517
Beyond the preview
Go deeper on NCT07220889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220889.